Asset Details
Do you wish to reserve the book?
The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer
Do you wish to request the book?
The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer
2013
Overview
In 2010, the FOLFIRINOX regimen (bolus and infusional 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) emerged as a new option in patients with metastatic pancreatic cancer and a good performance status. However, at that time, some doubts were raised regarding safety issues. Similarly, no data on FOLFIRINOX were published in patients with unresectable/locally advanced or borderline resectable pancreatic cancer. This article presents the available experience with FOLFIRINOX outside clinical trials in metastatic and locally advanced pancreatic cancer patients. The safety of the regimen in patients with biliary stents and in previously treated patients is also described. FOLFIRINOX usage in clinical practice, including modification of the regimen (omission of bolus 5-fluorouracil; FOLFOXIRI regimen), is also presented. These data suggest that a phase III randomized study is warranted to further explore the role of FOLFIRINOX in locally advanced pancreatic cancer.
Publisher
Current Science Inc,Springer Nature B.V,Current Medicine Group
Subject
/ Adenocarcinoma - drug therapy
/ Antineoplastic Combined Chemotherapy Protocols
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Camptothecin - administration & dosage
/ Camptothecin - analogs & derivatives
/ Fluorouracil - administration & dosage
/ Gastrointestinal Cancers (BG Czito
/ Humans
/ Leucovorin - administration & dosage
/ Medicine
/ Oncology
/ Organoplatinum Compounds - administration & dosage
/ Pancreatic Neoplasms - drug therapy
